Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021, with a specific transaction date of April 28, 2021. The document serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of January 1, 2021, to March 31, 2021.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions involving the following instruments and prices:
- Ordinary Shares (GBP): Priced at £13.40 per share (ISIN: GB0009252882).
- American Depositary Shares (USD): Priced at $37.75 per ADS (ISIN: US37733W1053).
Material Changes
The filing reports the acquisition of notional shares by eight Non-Executive Directors. There are no material changes to the company's financial position or operations reported in this document, as it is a regulatory disclosure of director compensation in the form of equity.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risks, contingencies, or unusual items. The document is strictly a notification of transactions executed on April 28, 2021.
Important Facts for Investors
- Transaction Type: All reported transactions are acquisitions of notional shares/ADSs as part of standard share allocation arrangements for Non-Executive Directors.
- Participants: Transactions were executed for Sir Jonathan Symonds, Mr. Charles Bancroft, Mr. Vindi Banga, Dr. Vivienne Cox, Ms. Lynn Elsenhans, Dr. Laurie Glimcher, Dr. Jesse Goodman, Ms. Judy Lewent, and Mr. Urs Rohner.
- Valuation Basis: The allocations were valued at £13.40 for Ordinary Shares and $37.75 for ADSs.
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or other periodic reports for financial performance data.